Results 201 to 210 of about 30,927 (236)
Some of the next articles are maybe not open access.
2014
Abnormal B-cell receptor (BCR) signaling is a key mechanism of disease progression in B-cell malignancy. Bruton's tyrosine kinase (BTK) has a pivotal role in BCR signaling. Ibrutinib (PCI-32765) is a novel agent which serves as a covalent irreversible inhibitor of BTK. It is characterized by high selectivity for BTK and high potency.
Mark-Alexander, Schwarzbich +1 more
openaire +2 more sources
Abnormal B-cell receptor (BCR) signaling is a key mechanism of disease progression in B-cell malignancy. Bruton's tyrosine kinase (BTK) has a pivotal role in BCR signaling. Ibrutinib (PCI-32765) is a novel agent which serves as a covalent irreversible inhibitor of BTK. It is characterized by high selectivity for BTK and high potency.
Mark-Alexander, Schwarzbich +1 more
openaire +2 more sources
Ibrutinib in the management of Waldenstrom macroglobulinemia
Journal of Oncology Pharmacy Practice, 2018Bruton tyrosine kinase plays a critical role in hastening cell proliferation. Bruton tyrosine kinase inhibitors are a class of immunotheraputic agents that disrupt this signaling pathway. Ibrutinib, a novel Bruton tyrosine kinase inhibitor approved by the Food and Drug Administration (FDA) for the treatment of Waldenstrom macroglobulinemia in patients
Amir Yosef +2 more
openaire +3 more sources
The Muddied Waters of Ibrutinib Therapy
Acta Haematologica, 2019A 37-year-old male was admitted with an atypical presentation of central nervous system (CNS) aspergillosis while on ibrutinib therapy for a CNS relapse of mantle cell lymphoma. This case highlights the importance of a high clinical suspicion of opportunistic infections in patients receiving small-molecule kinase inhibitors.
Miri Schamroth Pravda +2 more
openaire +3 more sources
Three years of ibrutinib in CLL
Blood, 2015In this issue of Blood, Byrd et al provide an important update on the prolonged efficacy and the limited and reducing toxicity of the single-agent Bruton tyrosine kinase inhibitor ibrutinib in chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma patients who are followed for a median time of 3 years from start of treatment.
openaire +4 more sources
2017
Ibrutinib (Imbruvica, Pharmacyclics, Janssen) is the first-in-class irreversible inhibitor of Bruton's tyrosine kinase (BTK), which is positioned downstream of the BCR at the cell surface of normal and malignant B-cells. In 2013, the Food and Drug Administration (FDA) granted accelerated approval for the treatment of mantle-cell lymphoma (MCL), and in ...
openaire +2 more sources
Ibrutinib (Imbruvica, Pharmacyclics, Janssen) is the first-in-class irreversible inhibitor of Bruton's tyrosine kinase (BTK), which is positioned downstream of the BCR at the cell surface of normal and malignant B-cells. In 2013, the Food and Drug Administration (FDA) granted accelerated approval for the treatment of mantle-cell lymphoma (MCL), and in ...
openaire +2 more sources
Risk of Major Bleeding with Ibrutinib
Clinical Lymphoma Myeloma and Leukemia, 2018The Bruton tyrosine kinase inhibitor, ibrutinib, is an effective therapy against mature B-cell malignancies. Although generally well tolerated, serious bleeding emerged during developmental clinical trials as an unexpected, although uncommon, adverse event.
Jeremy M Sen +8 more
openaire +3 more sources
Ibrutinib: targeting the hidden CLL
Blood, 2014In this issue of Blood , Herman et al elucidate the in vivo effects of ibrutinib (a BTK inhibitor) in various disease compartments of patients with chronic lymphocytic leukemia (CLL).[1][1] The study validates the differential impact of ibrutinib in various tumor compartments of patients treated ...
openaire +3 more sources
Ibrutinib and Cardiac Arrythmias
2021Patient was a 60-year-old male presented with palpitation. He had background history of diabetes type 2, obstructive sleep apnea on CPAP and hypertension.
openaire +2 more sources
Current Treatment Options in Oncology, 2014
The standard frontline therapy for diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL) includes the use of chemoimmunotherapy and/or radiation therapy. When patients with these diseases relapse or are refractory to therapy, their diseases are considered incurable outside of the setting of an autologous or ...
Kristie A. Blum, Kami J. Maddocks
openaire +2 more sources
The standard frontline therapy for diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL) includes the use of chemoimmunotherapy and/or radiation therapy. When patients with these diseases relapse or are refractory to therapy, their diseases are considered incurable outside of the setting of an autologous or ...
Kristie A. Blum, Kami J. Maddocks
openaire +2 more sources
Ibrutinib for Mantle Cell Lymphoma
Future Oncology, 2016Mantle cell lymphoma (MCL) is a rare and aggressive form of non-Hodgkin lymphoma. Ibrutinib is a first-in-class, oral inhibitor of Bruton's tyrosine kinase which acts by downstream inhibition of the B-cell receptor. Early clinical trials have demonstrated excellent tolerability and a modest side-effect profile in relapsed/refractory MCL.
David L. Tucker, Simon Rule
openaire +3 more sources